Demant A/S(0RGT)
DKK --+0.00%
Reward60Moderate
Risk27Low
📊50%Data
0RGT
+0.0 · +0.00%
DKK · LSE
Demant A/S |
Quality Compounder
Market Cap:67.04Bn
ℹ️
Reward Rating
60
Moderate
Top 50% (model universe)
50% data coverage
ℹ️
Risk Rating
27
Low
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on 0RGT to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Demant A/S?

Demant A/S operates as a hearing healthcare company in Europe, North America, Asia, Pacific region, and internationally.

0RGT · Verdict

Solid reward · low risk

0RGT scores well on cash flow and profitability with no major weaknesses flagged in the model.

Based on 75% data coverage

0RGT · Verdict

What’s working & what to watch

Strengths 4

  • Cash flow80/100

    Top decile vs peers

  • Profitability75/100

    24% return on equity

  • Balance sheet72/100

    Current ratio 0.87

  • Volatility65/100

    Above average

No major weaknesses flagged.

Model-based scoring. For information only — not financial advice.

What is Demant A/S?

Demant A/S operates as a hearing healthcare company in Europe, North America, Asia, Pacific region, and internationally. It engages in the development, manufacture, and wholesale of hearing aids; owning and operating hearing care clinics; and offers hearing and balance assessment solutions used by audiologists, ENT doctors, and balance clinics. The company is listed on the LSE in UK, with a market capitalisation of 67.04B.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Strong margins and consistent earnings support financial stability.
⚠️ Risk
Below-average volatility supports a steadier risk profile.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (60)

The scoring profile indicates moderate reward potential, with profitability and valuation as the leading contributors. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Company Information
SectorN/A
Market Cap67.04B
P/E RatioN/A
Dividend YieldN/A
52 Week High292.8
52 Week Low175
Last AnnualDecember
IPO DateN/A
IncorporatedUK
Shares OutstandingN/A
No. of Employees23,450
IndustryN/A
ExchangeLSE
Beta0.742
CurrencyDKK